このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

Portrayal of Hospital Alcohol Detoxification in France (Alcostop)

2021年10月18日 更新者:University Hospital, Montpellier

Portrayal of Hospital Alcohol Detoxifications and Factors Associated With Longer or Ulterior Hospitalizations in France From 2011 to 2020

Even if hospital alcohol detoxifications are frequent in France, their caracteristicscharacteristics remain unknown. The investigators aim to describe the clinical and paraclinical caracteristicscharacteristics of their patients, their length and geographical repartition, etc… The investigators also aim to evaluate factors associated with longer stays or ulterior re-hospitalization for the same reason. Finally, The investigators aim to compare the stays by facility type.

調査の概要

詳細な説明

Context:

In France, the consequences of excessive alcohol use are one of the primary reasons for hospitalization. When stopping the substance, patients with an alcohol use disorder can suffer from a potentially fatal alcohol withdrawal syndrome. To mitigate these risks, a withdrawal under medical supervision is possible, either in an outpatient setting or in hospital, where the detoxification can be programmed or imposed. In the course of an alcohol dependent patient's life, re-drinking is not exceptional and the patient may undergo several withdrawals during his or her life.

Psychiatric pathologies, especially anxiety and depression, are more frequent in these patients than in the rest of the population, just as can be somatic pathologies.e. Withdrawal accidents, represented by comital seizures and delirium tremens, can be critical.

In hospital detoxifications, studies do not show any benefit in continuing the stay beyond 10 days, except in the case of somatic or psychiatric complication. However, little information is available on the average length of stay for hospital alcohol detoxification.

Although alcohol dependence issues are very frequent and the resulting withdrawals are relatively common and associated with numerous comorbidities, little data exists at a national level in France.

The aim of this study is to describe these hospital detoxifications: course, duration, frequency and clinical and paraclinical characteristics of the patients. We also wish to analyze which characteristics are associated with longer stays or re-hospitalization and to compare the care according to the facility type.

Objectives:

Main:

- To describe the clinical, paraclinical, and stay characteristics of hospital alcohol detoxification in France

Secondary:

  • To describe the regional distribution of hospital alcohol detoxification
  • To evaluate whether certain clinical characteristics are associated with a longer hospital stays
  • To evaluate whether certain clinical characteristics are associated with subsequent re-hospitalization for the same reason
  • To compare the characteristics of patient stays by type of facility

Methods:

In this descriptive observational study using pre-existing data accessed via the PMSI (Programme de Médicalisation des Systèmes d'Information), we will use all hospital stays from 2011 to 2020 for alcohol detoxification in France, both in public and private settings.

For each hospital stay will be collected the length, the antecedents of hospital alcohol detoxification, clinical and psychiatric comorbidities, withdrawals complication, alcohol use complication, further examinations.

We will describe the stays using median and quartiles for continuous variables and number and percentage for dichotomous variables. For secondary objectives, we will use a multivariate linear regression model if the length of stay is normal, an ordinal regression model otherwise. The characteristics of the stays will be compared regarding the type of facility using univariate comparative tests: Chi² or Fisher for dichotomous variables and Student or Mann-Whitney for continuous variables.

研究の種類

観察的

入学 (実際)

50000

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

      • Montpellier、フランス、34295
        • Uhmontpellier

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年歳以上 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

サンプリング方法

非確率サンプル

調査対象母集団

French patients hospitalized for alcohol detoxification from 2011 to 2020

説明

Inclusion criteria:

Inclusion criteria:

  • French patients of at least 18 years old
  • Inpatients of a public or private care facility for alcohol detoxification
  • From 01/01/2011 to 12/31/2020
  • In a medical or psychiatric hospital

Exclusion criteria:

- age < 18 years

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

コホートと介入

グループ/コホート
介入・治療
Inpatients for alcohol detoxifications
French patients who were hospitalized for alcohol detoxification from 2011 to 2020
Stay for alcohol detoxification : routine care.

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
description of age
時間枠:day 1 (At hospital inclusion)
Age at admission (in years), calculated by the difference of the year of admission and the year of birth through the PMSI.
day 1 (At hospital inclusion)
description of sex
時間枠:day 1 (At hospital inclusion)
Sex collected through the PMSI.
day 1 (At hospital inclusion)

二次結果の測定

結果測定
メジャーの説明
時間枠
description of geographic code
時間枠:day 1 (At hospital inclusion)
Sex collected through the PMSI.
day 1 (At hospital inclusion)
description of CMU-C
時間枠:day 1 (At hospital inclusion)
CMU-C (universal complementary health insurance, collected through the PMSI.
day 1 (At hospital inclusion)
Length of stay
時間枠:During the stay (day 1 - day 15)
Length of stay (in days), calculated by the difference between the discharge date and the entry date, collected through the PMSI.
During the stay (day 1 - day 15)
Care establishment
時間枠:During the stay (day 1 - day 15)
Name and type of the care establishment, collected through the PMSI.
During the stay (day 1 - day 15)
Number of previous hospital detoxification stays in the studied period
時間枠:During the stay (day 1 - day 15)
Number of previous hospital detoxification stays in the studied period, collected through the PMSI.
During the stay (day 1 - day 15)
Psychiatric comorbidities
時間枠:During the stay (day 1 - day 15)
Psychiatric comorbidities (Major depression episode, anxiety, psychotic trouble, personality diseases), collected through the PMSI.
During the stay (day 1 - day 15)
Withdrawal complication
時間枠:During the stay (day 1 - day 15)
Withdrawal complications (delirium tremens, comitial seizures), collected through the PMSI.
During the stay (day 1 - day 15)
Further examination
時間枠:During the stay (day 1 - day 15)
Further examination (biology, imagery, etc…), collected through the PMSI.
During the stay (day 1 - day 15)
Re-hospitalization for same reason
時間枠:day 1
For each patient, and each stay, we will evaluate if the patient had an ulterior re-hospitalization for alcohol withdrawal. Collected through the PMSI.
day 1

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

捜査官

  • 主任研究者:Lionel MOULIS、University Hospital, Montpellier

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2021年5月1日

一次修了 (実際)

2021年8月30日

研究の完了 (実際)

2021年8月30日

試験登録日

最初に提出

2021年7月6日

QC基準を満たした最初の提出物

2021年7月21日

最初の投稿 (実際)

2021年7月22日

学習記録の更新

投稿された最後の更新 (実際)

2021年10月19日

QC基準を満たした最後の更新が送信されました

2021年10月18日

最終確認日

2021年10月1日

詳しくは

本研究に関する用語

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

未定

IPD プランの説明

NC

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する